A carregar...

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin. There were two partial responses lasting 40 and 105 weeks respectively. In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lind, M. J., Cantwell, B. M., Millward, M. J., Robinson, A., Proctor, M., Simmons, D., Carmichael, J., Harris, A. L.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1992
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977567/
https://ncbi.nlm.nih.gov/pubmed/1314071
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!